Clinical Trials
9 trialsNCT02834013 2026-06-03
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02978625 2026-05-13
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06873815 2026-01-12
A Study of Fluorescein Sodium in People Undergoing Vulvectomy for Extramammary Paget's Disease (EMPD)
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07309770 2025-12-30
Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies
Fudan University
Phase 2 Recruiting
NCT06683846 2025-08-24
Ivonescimab in the Treatment of Multiple Advanced Tumors
Fudan University
Phase 2 Recruiting
NCT07117851 2025-08-12
A Study of Disitamab Vedotin + Bicalutamide in HER2/AR-Positive Scrotal Paget's Disease
Fudan University
Phase 2 Recruiting
NCT06791070 2025-01-24
RC48&J for EPD
Fujian Medical University Union Hospital
Phase 2 Recruiting
NCT06684327 2024-12-20
Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors
Fudan University
Phase 2 Recruiting
NCT06561555 2024-12-17
A Study on the Efficacy of Disitamab Vedotin in Advanced HER2-positive Paget's Disease.
Fudan University
Phase 2 Recruiting